Doug Ball named interim president of Pittsburg State University
'I did grow up right here in southeast Kansas, mostly in Baxter Springs, just south of here and so Pitt State was something that was kind of always in my environment, always in my awareness,' said Doug Ball, PSU Interim Pres.
So it was an easy decision when Doug Ball decided to get his undergraduate degree at Pittsburg State University. He earned a Bachelor's degree in Business Administration… and he isn't the only one in the family who's a Gorilla.
'My father also attended here. In fact, I was born in Pittsburg while my father was a student here at Pittsburg State, and so Pittsburg State's been part of my life from day one, in some ways, literally. And so it's been exciting to be here at different times in my life and different capacities,' said Ball. That includes his career path.
Doug Ball named interim president of Pittsburg State University
Doug Ball named interim president at Pittsburg State University
ROTC Commissioning Ceremony held at PSU
PSU nursing student overcomes barriers and achieves her dream
Ball joined PSU as the Chief Financial Officer and Vice President for Administration eight years ago.
'There's really two major components of my job responsibilities, finance and facilities. So on the finance side, it's everything from accounting to budgeting and purchasing. Also that fits in there is our human resources team is part of the organization. And then on the facility sides, the planning and maintenance and care for our facilities on campus.'
He's now adding to those responsibilities, officially taking over at interim PSU president from Dr. Dan Shipp who is moving on to head Maryville University.
'It's all about keeping us moving forward on the critical projects we've got going on,' said Ball.
Ball adds that he loves Pitts State, which is a great motivation for the extra challenges that lie ahead.
'I had a fantastic impact to my life and my career as a result of my time here as a student. And I love the chance to see that repeated for students over and over again.'
Ball is serving as president on a short-term basis while the Kansas Board of Regents searches for a permanent replacement… a decision that school leaders say could take several months.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Baxter (BAX) Reports Earnings Tomorrow: What To Expect
Healthcare company Baxter International (NYSE:BAX) will be reporting earnings this Thursday before market hours. Here's what to expect. Baxter beat analysts' revenue expectations by 1.9% last quarter, reporting revenues of $2.63 billion, up 5.4% year on year. It was a very strong quarter for the company, with a solid beat of analysts' constant currency revenue estimates and an impressive beat of analysts' EPS estimates. Is Baxter a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Baxter's revenue to grow 4.7% year on year to $2.82 billion, in line with the 4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.61 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Baxter has missed Wall Street's revenue estimates six times over the last two years. Looking at Baxter's peers in the medical devices & supplies - diversified segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.8%, beating analysts' expectations by 3.4%, and Neogen reported a revenue decline of 4.8%, topping estimates by 1.3%. Boston Scientific traded up 2.9% following the results. Read our full analysis of Boston Scientific's results here and Neogen's results here. Investors in the medical devices & supplies - diversified segment have had fairly steady hands going into earnings, with share prices down 1.8% on average over the last month. Baxter is down 5.2% during the same time and is heading into earnings with an average analyst price target of $37.09 (compared to the current share price of $28.70). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Monolithic Power Systems (MPWR) To Report Earnings Tomorrow: Here Is What To Expect
Power management chips maker Monolithic Power Systems (NASDAQ:MPWR) will be reporting results this Thursday after the bell. Here's what you need to know. Monolithic Power Systems beat analysts' revenue expectations by 0.7% last quarter, reporting revenues of $637.6 million, up 39.2% year on year. It was a mixed quarter for the company, with a narrow beat of analysts' EPS estimates but an increase in its inventory levels. Is Monolithic Power Systems a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Monolithic Power Systems's revenue to grow 28.5% year on year to $652.1 million, improving from the 15% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $4.12 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Monolithic Power Systems has a history of exceeding Wall Street's expectations, beating revenue estimates every single time over the past two years by 1.6% on average. Looking at Monolithic Power Systems's peers in the analog semiconductors segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Texas Instruments delivered year-on-year revenue growth of 16.4%, beating analysts' expectations by 2%, and Sensata Technologies reported a revenue decline of 8.9%, topping estimates by 1.1%. Texas Instruments traded down 13.3% following the results. Read our full analysis of Texas Instruments's results here and Sensata Technologies's results here. There has been positive sentiment among investors in the analog semiconductors segment, with share prices up 4.6% on average over the last month. Monolithic Power Systems's stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $809.92 (compared to the current share price of $726). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 hours ago
- Yahoo
SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 5, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1130215. The archived webcast will be available in the Investor Relations section of the Company's website. About SIGA SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world's most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit Contacts:Suzanne Harnettsharnett@ and Investors Media Jennifer Drew-Bear, Edison GroupJdrew-bear@ Holly Stevens, CG Lifehstevens@
